Stock analysts at Barclays initiated coverage on shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) in a report issued on Tuesday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $11.00 price target on the stock. Barclays‘s target price would suggest a potential upside of 271.62% from the stock’s current price.
OSMT has been the subject of several other reports. Zacks Investment Research cut Osmotica Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, June 7th. Wells Fargo & Co set a $14.00 price objective on Osmotica Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, March 28th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Osmotica Pharmaceuticals has an average rating of “Buy” and a consensus price target of $14.00.
OSMT opened at $2.96 on Tuesday. Osmotica Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $9.90. The firm has a market cap of $121.59 million and a P/E ratio of -5.80. The company has a quick ratio of 1.41, a current ratio of 1.70 and a debt-to-equity ratio of 0.71.
Large investors have recently added to or reduced their stakes in the company. Northern Trust Corp acquired a new position in shares of Osmotica Pharmaceuticals during the 4th quarter worth about $615,000. BlackRock Inc. acquired a new position in shares of Osmotica Pharmaceuticals during the 4th quarter worth about $3,682,000. Broadfin Capital LLC acquired a new position in shares of Osmotica Pharmaceuticals during the 4th quarter worth about $4,096,000. Millennium Management LLC acquired a new position in shares of Osmotica Pharmaceuticals during the 4th quarter worth about $2,568,000. Finally, Great Point Partners LLC acquired a new position in shares of Osmotica Pharmaceuticals during the 4th quarter worth about $11,625,000. 11.64% of the stock is owned by institutional investors and hedge funds.
Osmotica Pharmaceuticals Company Profile
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.
Further Reading: Are Wall Street analysts’ stock ratings worth following?
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.